Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00232726
Other study ID # CP4055-201
Secondary ID
Status Completed
Phase Phase 2
First received October 4, 2005
Last updated July 9, 2007
Start date September 2005
Est. completion date July 2007

Study information

Verified date July 2007
Source Clavis Pharma
Contact n/a
Is FDA regulated No
Health authority Norway: Norwegian Medicines AgencyUnited States: Food and Drug AdministrationSweden: Medical Products Agency
Study type Interventional

Clinical Trial Summary

Previously untreated patients with malignant melanoma receive a new chemotherapy drug currently under development. CP-4055 is given intravenously on days 1-5 every four weeks until complete response or disease progression.


Description:

This is an international multicentre phase II clinical study conducted in the USA and Europe. Previously untreated patients over 18 years, with metastatic malignant melanoma are eligible for inclusion if they fulfil all inclusion- and exclusion criteria. 16 or 42 patients will be enrolled in Pittsburgh USA, Lund Sweden and Oslo Norway.

The new development drug CP-4055 is administered for five consecutive days (Day 1 to 5) in a 4 week schedule (one cycle). The dose is 200 mg/m2/day.

A patient will continue treatment until complete response or until (s)he is withdrawn from the Clinical Study because of disease progression, unacceptable toxicity or any other reason described in the clinical study protocol.

Efficacy is assessed at baseline and end of every second cycle with CT or MRI.

Safety assessments are done at each visit. Blood samples are taken and haematological and biochemical parameters are assessed for safety.

Any adverse events are recorded and reported.

The clinical study has been approved by the relevant Independent Ethical Committees/Institutional Review Boards and Concerned Regulatory Authority as appropriate. It is conducted according to ICH Good Clinical Practice, the Declaration of Helsinki, and applicable national law and regulations.

Patients who give an additional consent will have two additional, and not mandatory, procedures performed:

- Biopsy (tissue sample) from particular tumours (taken only at baseline for identification of tumour genes)

- Serum samples (from blood drawn at baseline and at end of the cycle 2 for protein sequences analyses, proteomics)


Recruitment information / eligibility

Status Completed
Enrollment 42
Est. completion date July 2007
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients with histologically or cytologically confirmed stage IV or unresectable stage III non-ocular malignant melanoma who have not undergone prior chemotherapy for the treatment of melanoma (chemotherapy-naïve)

- Measurable disease according to Response Criteria in Solid Tumours (RECIST)

- Performance Status 0 – 2 according to ECOG (Eastern Cooperative Oncology Group) Performance Status

- Age 18 years or more

- Life expectancy > 3 months

- Signed informed consent

- Adequate haematological and biological functions:

- Bone marrow function:

1. Neutrophils = 1.5 x 10^9/L

2. Platelets = 100 x 10^9/L

3. Hemoglobin (Hb) = 10 g/dL

- Hepatic function:

1. AST/ALT = 2.5 times institutional upper limit of normal (ULN). If liver metastases, = 5 times institutional ULN.

2. Serum bilirubin and alkaline phosphatase = 1.5 times institutional ULN

- Renal function:

- Creatinine = 1.5 times institutional ULN

Exclusion Criteria:

- Known brain metastases

- Diagnosis of ocular malignant melanoma

- Radiotherapy to more than 30% of bone marrow

- Participation in another therapeutic clinical study within 30 days of enrolment or during this clinical study

- Prior immunotherapy and/or chemotherapy for the treatment of melanoma

- Requirement of concomitant treatment with a non-permitted medication:

- Alternative drugs

- High doses of vitamins

- History of allergic reactions to Ara-C or egg

- Presence of any serious concomitant systemic disorders incompatible with the clinical study (e.g. uncontrolled intercurrent illness including ongoing or active infection)

- Presence of any significant central nervous system or psychiatric disorder(s) that would hamper the patient’s compliance

- Pregnancy, breastfeeding, or absence of adequate contraception for both male and female fertile patients

- Known positive status for HIV and/or hepatitis B or C

- Drug and/or alcohol abuse

- Any reason why, in the Investigator’s opinion, the patient should not participate

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
CP-4055 (ELACYT)


Locations

Country Name City State
Norway The Norwegian Radium Hospital Oslo
Sweden University Hospital Lund
United States University of Pittsburgh Pittsburgh Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
Clavis Pharma

Countries where clinical trial is conducted

United States,  Norway,  Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Primary Objective tumour response
Secondary Time to progression
Secondary Duration of tumour response
Secondary Safety and tolerability of treatment
See also
  Status Clinical Trial Phase
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Terminated NCT03166631 - A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread Phase 1
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Active, not recruiting NCT03775980 - CIRSE Emprint Microwave Ablation Registry
Completed NCT01114958 - Pilot Study of Intra-Arterial Cisplatin With IV Thiosulfate in Patients With Lung Cancer or Lung Metastases Phase 1
Terminated NCT03986593 - Cryoablation of Bone Metastases From Endocrine Tumors N/A
Active, not recruiting NCT04458259 - Study of PF-07265807 in Participants With Metastatic Solid Tumors. Phase 1
Completed NCT01218542 - Whole Brain Radiation Therapy With Boost to Metastatic Tumor Volume Using RapidArc N/A
Not yet recruiting NCT03175146 - A Study to See Whether Stereotactic Body RadioTherapy (SBRT) Can Shrink Tumours Within the Liver Safely N/A
Active, not recruiting NCT02395224 - A Longitudinal Study of Colorectal Cancer Patients With Metastatic Disease in Middle-Norway
Completed NCT02374411 - Knowledge, Attitudes, and Practice of Surgeons Toward Nutrition Support in HIPEC Patients N/A
Recruiting NCT01960829 - Everolimus in Selected Patients With Metastatic Melanoma: Efficacy and Safety Study Phase 2
Terminated NCT01846429 - Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain Phase 1
Completed NCT01933789 - Improving Communication About Serious Illness N/A
Recruiting NCT01564810 - Cetuximab in Combination With Chemotherapy for the Treatment of Metastatic Colorectal Cancer Phase 4
Completed NCT00375245 - Rapamycin With Grapefruit Juice for Advanced Malignancies Phase 1
Completed NCT00207116 - An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastatic Non Small Cell Lung Carcinoma Phase 1
Completed NCT00207103 - MAD in Cancer Patients: Safety of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors Phase 1
Completed NCT00172003 - Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis Phase 4
Completed NCT00094003 - Study of NS-9 in Patients With Liver Metastases Phase 1

External Links